Theracryf Plc (AIM:TCF)

Revenue by Segment

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Development of Pharmaceutical Products	396.00K	442.00K	-	194.00K
Development of Pharmaceutical Products Growth	-10.41%	-	-	-
Total	396.00K	442.00K	-	194.00K
Total Growth	-10.41%	-	-	-

Revenue by Geography

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
United Kingdom	396.00K	442.00K	-	194.00K
United Kingdom Growth	-10.41%	-	-	-
Total	396.00K	442.00K	-	194.00K
Total Growth	-10.41%	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 16, 2026

Data Sources Report a data error